#United States #Carlsbad #Infectious Disease #SeqOnce Biosciences #Measles Panel

SeqOnce Biosciences Expands Pathogen Assay Suite

SeqOnce Biosciences, based in Carlsbad, California, has announced a significant enhancement to its pathogen assay offerings with the introduction of the RT-qPCR Measles Panel. This innovative tool is designed to cater to the growing demand for reliable assays in infectious disease research, particularly as measles cases have seen a concerning rise in the United States. The launch of the Measles Panel A highlights the company's commitment to developing cutting-edge genomic tools that serve various stages of pathogen analysis, from early development to clinical application.

Commitment to Innovation

Chris Angermayer, CEO of SeqOnce, emphasized the company's dedication to improving diagnostics in the infectious disease sector. He stated, “This expansion ensures we can effectively partner throughout our customers' pathogen analysis journey, covering all stages from development to clinical research.” SeqOnce’s focus on innovation is paired with a commitment to safety, as the company aims to provide genomic tools that help safeguard public health and the environment.

About the Measles Panel A

The newly developed Measles Panel A is compatible with established qPCR systems from Bio-Rad, Roche, and ABI. It has been specifically formulated to detect the D8 genotype, which has been linked to recent measles outbreaks in the U.S. Importantly, this panel is capable of identifying all known circulating strains of the virus, making it a versatile tool for laboratories and health professionals working to combat the disease.

Customer-Centric Development

The development of SeqOnce's Measles Panel A reflects the company’s strategy of engaging directly with customers to understand their needs based on market trends. Joe Dunham, Chief Science Officer, noted, “By collaborating with our customers, we can identify gaps in the market and leverage our bioinformatics capabilities to design tailored panels.” This approach not only ensures high-quality products but also enhances the integration of SeqOnce's other offerings, creating a seamless experience for users.

Comprehensive Product Portfolio

SeqOnce’s commitment to addressing diverse health challenges is evidenced in its product portfolio, which includes multiplex qPCR assays for respiratory diseases, women’s health, and antibiotic resistance. This wide range of products positions SeqOnce as a key player in the field of genomics, particularly for infectious diseases. For more information on their offerings, customers are encouraged to visit SeqOnce's official website.

Overview of SeqOnce, Inc.

Founded as a privately held company, SeqOnce Biosciences operates out of Carlsbad, CA, dedicated to advancing genomic tools related to infectious diseases and developing novel platforms for research purposes. The company continues to explore innovative solutions that empower researchers and healthcare professionals in their fight against infectious diseases. Interested individuals can reach out to Chris Angermayer at 1 (626) 460-3050 for further inquiries regarding their products and services.